Activated c-Abl tyrosine kinase in malignant solid tumors (Q37129818)

18 August 2017

1 reference

title

Activated c-Abl tyrosine kinase in malignant solid tumors (English)

1 reference

18 August 2017

J Lin

1

1 reference

PubMed ID

18391983

18 August 2017

R Arlinghaus

series ordinal

2

1 reference

PubMed ID

18391983

18 August 2017

language of work or name

English

0 references

publication date

7 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

27

1 reference

18 August 2017

32

1 reference

18 August 2017

4385-4391

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2008.86

18 August 2017

0 references

cites work

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Chasing mutations in the epidermal growth factor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

A myristoyl/phosphotyrosine switch regulates c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Molecular and cellular aspects of the insulin-like growth factor I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

The Abl family kinases: mechanisms of regulation and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

21 January 2018

Autoinhibition of c-Abl

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Regulation of cell death by the Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Molecular responses to hypoxia in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.86

31 March 2020

Identifiers

DOI

10.1038/ONC.2008.86

1 reference

18 August 2017

1 reference

PubMed ID

18391983